对多巴胺D2受体的积极体调节器的脂质暴露的额外螺旋结合部位的识别2
Herman D Lim1, Damian Bartuzi2,3, Alastair C Keen1,4,5
1Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 399 Royal Parade, Parkville, VIC 3052, Australia.
ACS chemical neuroscience
|May 15, 2025
概括
研究人员发现了多巴胺D2受体 (D2R) 的新型小分子正调节剂 (PAM). 这些PAMs通过通过一个独特的全结合部位增强D2R信号传递,显示出对帕金森病治疗的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 多巴胺D2受体 (D2R) 在运动控制中起着至关重要的作用,是帕金森病治疗的关键标.
- 小分子正调剂 (PAMs) 提供了一个有前途的策略,以微调受体活性.
研究的目的:
- 为了识别和描述多巴胺D2受体的新型小分子PAM.
- 阐明这些D2R PAMs的全结合部位和作用机制.
主要方法:
- 局部导向的突变发生.
- 分子动力学模拟的模拟.
- 在体外受体信号测试中的受体信号测试.
- 与帕金森病相关的体内疗效模型.
主要成果:
- 对D2R.第一个小分子PAMs的识别.
- 领先的PAM在体外证明了D2R信号的增强,并在体内证明了抗帕金森症的有效性.
- 一个新的,暴露于脂质的,外螺旋性全结合部位的表征,涉及跨膜域1和7和螺旋8.
- 机制涉及稳定活性类受体构造,增强激素结合亲和力.
结论:
- 开发了针对D2R上独特的全位点的新型小分子PAM.
- 这些D2R PAMs代表了帕金森病的潜在新疗法途径.
- 了解全调节机制,可以了解D2R调节.
相关概念视频
Ligand Binding and Linkage
4.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K
Ligand Binding Sites
12.6K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.6K
Allosteric Regulation
57.2K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.2K
Allosteric Proteins-ATCase
5.6K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K
The Two-State Receptor Model
1.8K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.8K
Cooperative Allosteric Transitions
7.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.8K


